The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and health systems.
PARADIGM SHIFTS, ESPECIALLY IN MEDICINE, DO NOT HAPPEN JUST BECAUSE THE SCIENCE AND NEW TECHNOLOGIES SUGGEST THEY SHOULD.

Based on this assumption, some 20 institutions launched the Personalized Medicine Coalition in 2004 to develop a new medical paradigm that links treatment decisions to diagnostics.

Believing in an ecosystem of shared value across the multiple stakeholders it represents, the Coalition advocates for changes that will increase investment in personalized medicine and facilitate its clinical adoption so that both patients and health systems will benefit from improved health care and increased efficiency.

WHAT IS PERSONALIZED MEDICINE?

Personalized medicine is an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each patient or use medical interventions to alter molecular mechanisms that impact health. By combining data from diagnostic tests with an individual’s medical history, circumstances and values, health care providers can develop targeted treatment and prevention plans with their patients.
PMC WORKS TO ENSURE THAT POLICIES AND PRACTICES IN THE PUBLIC AND PRIVATE SECTORS PAVE THE WAY FOR PERSONALIZED MEDICINE.

Based in Washington, D.C., PMC works closely with health systems, lawmakers and agency officials to advance strategic priorities in three areas:

- **Education:** To raise the profile and scope of personalized medicine, PMC proactively educates decision-makers and patients about how the field can make health systems more effective and efficient by targeting better treatments to only those who will benefit.

- **Advocacy:** To help facilitate the development of personalized medicine tests and therapies, PMC engages policymakers to advocate for continued investments in biomedical research as well as modernized regulatory, coverage and payment policies that support access to personalized medicine.

- **Evidence Development:** To encourage the swifter adoption of personalized medicine by payers and health care providers, PMC helps build the evidence base necessary to demonstrate the clinical and economic value of personalized medicine.

“Personalized medicine is transforming the practice of medicine, and PMC is playing a critical role in bringing together all of the stakeholders to help make that happen.”  
– Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Harvard Medical School
PMC MEMBERS ARE LEADING THE MOVEMENT TOWARD PERSONALIZED MEDICINE TO BENEFIT PATIENTS AND HEALTH SYSTEMS AROUND THE WORLD.

MEMBER COMMITTEES/WORKING GROUPS

- Public Policy Committee
  - Patient Advocacy Organization Working Group
  - Pharmaceutical and Diagnostics Working Group

- Science Policy Committee
  - Health Care Working Group
  - Value Assessment Working Group

- Additional Working Groups
  - Health Data Working Group
  - Pharmacogenomics Working Group

MEMBER BENEFITS

- Contact 2,000+ leaders in personalized medicine via PMC’s member database
- Interact with 200+ thought leaders from Congress, FDA, CMS and the private sector at member meetings and events
- Save 40% on registration for the Annual Personalized Medicine Conference

Attend Member Meetings and Events at no charge
Receive Copies of PMC publications and reports
PMC MEMBERSHIP

PMC is an international, multi-stakeholder 501(c)3 nonprofit organization with members that are committed to science-driven, evidence-based health care.

**CLINICAL LABORATORY TESTING SERVICES**
- Avellino Labs
- Invitae
- Laboratory Corporation of America (Labcorp)
- Quest Diagnostics

**DIAGNOSTIC COMPANIES**
- 10x Genomics
- Agilent Technologies
- Almac Diagnostics
- Ambry Genetics
- Biological Dynamics
- Caris Life Sciences
- Castle Biosciences
- Circulogene
- Cofactor Genomics
- Delfi Diagnostics
- Diaceutics
- Exact Sciences
- Exai Bio
- Foundation Medicine, Inc.
- GeneCentric Therapeutics
- Genetic Center – Regina Maria
- GRAIL, Inc.
- Guardant Health
- Illumina
- Kiyatec
- Myriad Genetics
- NanoString Technologies
- NeoGenomics Laboratories
- NuProbe, Inc.
- Olaris Therapeutics
- Oncocyte
- Personalis
- QIAGEN, Inc.
- Quibim
- Roche Diagnostics
- RxGenomix
- Scipher Medicine
- Singular Genomics
- SomaLogic, Inc.
- Thermo Fisher Scientific

**EMERGING BIOTECH/PHARMACEUTICAL COMPANIES**
- Adaptive Biotechnologies
- Alexion Pharmaceuticals
- American Diagnostics and Therapeutics (ADxRx)
- Elevation Oncology, Inc.
- Freenome
- Helix
- Kyverna Therapeutics
- MacroGenics
- SmartPGX

**HEALTH INSURANCE COMPANIES**
- Point32Health

**INDUSTRY/TRADE ASSOCIATIONS**
- American Clinical Laboratory Association
- Biocom California
- National Society of Genetic Counselors
- PhRMA

**IT/INFORMATICS COMPANIES**
- 2bPrecise
- Aetion
- Assurance Health Data
- Change Healthcare
- Concert Genetics
- DNAnexus
- Flatiron Health
- GNS Healthcare
- Lifebit
- M2Gen
- Nucleai
- P4-ML
- Paige.ai
- PathAI
- Ruffin Health
- Syapse
- Translational Software
- Verily Life Sciences
- XIFIN, Inc.

**LARGE BIOTECH/PHARMACEUTICAL COMPANIES**
- AbbVie
- Amgen, Inc.
- AstraZeneca Pharmaceuticals
- Bausch Health Companies
- Bayer
- Biogen
- Blueprint Medicines
- Bristol Myers Squibb
- Eli Lilly and Company
- Genentech, Inc.
- Gilead
- GlaxoSmithKline
- Johnson & Johnson
- Merck & Co.
- Novartis
- Pfizer, Inc.
- Sanofi

**PATIENT ADVOCACY GROUPS**
- Accelerated Cure Project for Multiple Sclerosis
- AiArthritis
- Alliance for Aging Research
- Alzheimer’s Foundation of America
- American Association of Kidney Patients (AAKP)
- American Association on Health and Disability (AAHD)
- American Cancer Society Cancer Action Network (ACS-CAN)
- Blue Hat Foundation
- Bulgarian Association for Personalized Medicine
- Cancer101
- Colorectal Cancer Alliance
- Emily’s Entourage
- EveryLife Foundation for Rare Diseases
- Friends of Cancer Research
As of January 2023

<table>
<thead>
<tr>
<th>Category</th>
<th>Dues Structure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Large Public Corporation</td>
<td>$34,000</td>
</tr>
<tr>
<td>Small Public Corporation</td>
<td>$17,000</td>
</tr>
<tr>
<td>Trade Association (based on revenues)</td>
<td></td>
</tr>
<tr>
<td>Private Corporation &gt;15 FTEs</td>
<td>$6,500</td>
</tr>
<tr>
<td>Professional Society (based on revenues)</td>
<td></td>
</tr>
<tr>
<td>Private Corporation &lt;15 FTEs</td>
<td>$3,200</td>
</tr>
<tr>
<td>Strategic Partner &gt;5 FTEs</td>
<td>$3,400</td>
</tr>
<tr>
<td>Strategic Partner &lt;5 FTEs</td>
<td>$1,600</td>
</tr>
<tr>
<td>Research, Education &amp; Clinical Care Institutions</td>
<td>$3,200</td>
</tr>
<tr>
<td>Patient Advocacy Group</td>
<td>$500</td>
</tr>
</tbody>
</table>

Visit [pmc.portal.membersuite.com](http://pmc.portal.membersuite.com) to join the Coalition.

For more information, contact Kayla Smith, Vice President, Membership & Development, at ksmith@personalizedmedicinecoalition.org.
STAFF

Edward Abrahams, Ph.D.
President

Faswilla Sampson
Chief Operating Officer

Cynthia A. Bens
Senior Vice President, Public Policy

Daryl Pritchard, Ph.D.
Senior Vice President, Science Policy

Christopher J. Wells
Senior Vice President, Public Affairs

Kayla Smith
Vice President, Membership & Development

David L. Davenport
Manager, Public Policy

Lindsay Stephens
Senior Operations Manager & Secretary to the Board

BOARD OF DIRECTORS

Lincoln Nadauld, M.D., Ph.D.
Chair
Culmination Bio, Inc.

Lauren Silvis
Vice Chair
Tempus

Mark P. Stevenson
Treasurer
General Atlantic

Michael Sherman, M.D.
Secretary
Point32Health

Antonio L. Andreu, M.D., Ph.D.
European Infrastructure for Translational Research (EATRIS)

Randy Burkholder
PhRMA

Kevin Conroy
Exact Sciences

William S. Dalton, Ph.D., M.D.
M2Gen

Stephen L. Eck, M.D., Ph.D.
MacroGenics

Lori Frank, Ph.D.
The New York Academy of Medicine

Sarah Hersey
Bristol Myers Squibb

Kris Joshi, Ph.D.
Change Healthcare

Richard Knight
American Association of Kidney Patients

Peter Maag, Ph.D.
Kyverna Therapeutics

Anne-Marie Martin, Ph.D.
GlaxoSmithKline

Howard McLeod, Pharm.D.
Intermountain Healthcare

J. Brian Munroe
Bausch Health Companies

Elizabeth O’Day, Ph.D.
Olaris, Inc.

Michael Pellini, M.D.
Section32

Kimberly J. Popovits
10x Genomics

Prahsanth Reddy, M.D.
Labcorp

Apostolia M. Tsimberidou, M.D., Ph.D.
The University of Texas MD Anderson Cancer Center

Michael J. Vasconcelles, M.D.
ImmunoGen

Jay G. Wohlgemuth, M.D.
Quest Diagnostics